MX2009011228A - Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento. - Google Patents

Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.

Info

Publication number
MX2009011228A
MX2009011228A MX2009011228A MX2009011228A MX2009011228A MX 2009011228 A MX2009011228 A MX 2009011228A MX 2009011228 A MX2009011228 A MX 2009011228A MX 2009011228 A MX2009011228 A MX 2009011228A MX 2009011228 A MX2009011228 A MX 2009011228A
Authority
MX
Mexico
Prior art keywords
cancer cells
neu
treatment
detection
neu protein
Prior art date
Application number
MX2009011228A
Other languages
English (en)
Inventor
Robert M Lorence
Ming Lu
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Publication of MX2009011228A publication Critical patent/MX2009011228A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La expresión de la proteína Her-2/neu en células cancerosas circulantes en una muestra de sangre o células mononucleares de sangre periférica (PBMCs) se detectan al realizar un inmunoensayo sensible a Her-2/neu. No hay la necesidad de aislar las células cancerosas antes de realizar el inmunoensayo. Un resultado positivo indica la expresión de Her-2/neu en células cancerosas en la muestra de sangre. Este método se puede utilizar para identificar pacientes con cáncer quienes es probable que se beneficien del tratamiento con un agente carcinostático que fija como objetivo la Her-2/neu, tal como trastuzumab (HERCEPTIN), lapatinib, CP-724,714, NKI-272 y BMS-599626.
MX2009011228A 2007-04-19 2008-04-15 Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento. MX2009011228A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91283307P 2007-04-19 2007-04-19
PCT/US2008/060317 WO2008130910A1 (en) 2007-04-19 2008-04-15 Detection her-2/neu protein from non-isolated circulating cancer cells and treatment

Publications (1)

Publication Number Publication Date
MX2009011228A true MX2009011228A (es) 2009-11-02

Family

ID=39875858

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011228A MX2009011228A (es) 2007-04-19 2008-04-15 Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.

Country Status (7)

Country Link
US (1) US20100120072A1 (es)
EP (1) EP2145188A4 (es)
JP (1) JP2010525326A (es)
CN (1) CN101663584A (es)
CA (1) CA2684265A1 (es)
MX (1) MX2009011228A (es)
WO (1) WO2008130910A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113952338A (zh) 2005-02-03 2022-01-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
CA2626326C (en) 2005-11-04 2021-02-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2835349T3 (es) 2008-06-17 2021-06-22 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN105963313A (zh) 2008-08-04 2016-09-28 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimens containing neratinib for the treatment of cancer
JP6082344B2 (ja) 2010-05-27 2017-02-15 ゲンマブ エー／エス Ｈｅｒ２エピトープに対するモノクローナル抗体
EP2576621B1 (en) 2010-05-27 2019-04-10 Genmab A/S Monoclonal antibodies against her2
US20140170149A1 (en) 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3
CN104122394A (zh) * 2013-04-23 2014-10-29 北京豪迈生物工程有限公司 人表皮生长因子受体2(Her-2)定量测定试剂盒及其检测方法
JP6245147B2 (ja) * 2014-11-19 2017-12-13 株式会社オートネットワーク技術研究所 モールド部付電線
CN104568923A (zh) * 2014-12-01 2015-04-29 浙江省肿瘤医院 电化学发光检测外周血循环肿瘤细胞抗原的方法及试剂盒
JP6323317B2 (ja) * 2014-12-09 2018-05-16 株式会社オートネットワーク技術研究所 端子付電線

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451225B1 (en) * 1986-04-30 2002-09-17 Igen International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US6448091B1 (en) * 1988-11-03 2002-09-10 Igen International, Inc. Method and apparatus for improved luminescence assays using particle concentration chemiluminescence detection
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
NO180658C (no) * 1994-03-10 1997-05-21 Oeystein Fodstad Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner
AU2365895A (en) * 1994-04-26 1995-11-16 Regents Of The University Of Michigan, The Unitary sandwich enzyme immunoassay cassette, device and method of use
US5744367A (en) * 1994-11-10 1998-04-28 Igen International, Inc. Magnetic particle based electrochemiluminescent detection apparatus and method
US6884357B2 (en) * 1995-02-21 2005-04-26 Iqbal Waheed Siddiqi Apparatus and method for processing magnetic particles
US5783404A (en) * 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
AU718767B2 (en) * 1995-06-07 2000-04-20 Bioveris Corporation Electrochemiluminescent enzyme immunoassay
US6117985A (en) * 1995-06-16 2000-09-12 Stemcell Technologies Inc. Antibody compositions for preparing enriched cell preparations
US6190870B1 (en) * 1995-08-28 2001-02-20 Amcell Corporation Efficient enrichment and detection of disseminated tumor cells
US6297062B1 (en) * 1996-03-07 2001-10-02 Bio-Magnetics Ltd. Separation by magnetic particles
US6890426B2 (en) * 1996-06-07 2005-05-10 Immunivest Corporation Magnetic separation apparatus and methods
BR9907852A (pt) * 1998-02-12 2000-10-24 Immunivest Corp Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO2000047998A1 (en) * 1999-02-10 2000-08-17 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
US6300143B1 (en) * 1999-03-01 2001-10-09 Idec Pharmaceuticals Corporation Electrochemiluminescent assays for eukaryotic cells
US6969615B2 (en) * 1999-07-26 2005-11-29 20/20 Genesystems, Inc. Methods, devices, arrays and kits for detecting and analyzing biomolecules
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
JP3313107B2 (ja) * 2001-03-22 2002-08-12 バイエル コーポレイション ヒトの生物学的流体中のｎｅｕ関連タンパク質の検出及び定量
DE10143776A1 (de) * 2001-09-06 2003-04-03 Adnagen Ag Verfahren und Kit zur Diagnostik oder Behandlungskontrolle von Brustkrebs
WO2003031938A2 (en) * 2001-10-11 2003-04-17 Aviva Biosciences Corporation Methods, compositions, and automated systems for separating rare cells from fluid samples
EP1597353B1 (en) * 2003-02-27 2010-11-24 Veridex, LLC CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS
ATE497165T1 (de) * 2004-10-06 2011-02-15 Wellstat Biologics Corp Erkennung eines erhöhten spiegels von her-2/neu- proteinen in zirkulierenden krebszellen und dessen behandlung
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
EP1816477A1 (en) * 2006-02-06 2007-08-08 F. Hoffmann-la Roche AG The use of natriuretic peptides and placenta growth factor levels for risk stratification of individuals elected for cardiac stress testing
EP2008102A4 (en) * 2006-04-18 2009-07-08 Wellstat Biologics Corp DETECTION OF PROTEINS IN NEOPLASTIC CELLS IN CIRCULATION
EP2008107A4 (en) * 2006-04-18 2009-12-23 Wellstat Biologics Corp DETECTION OF STEROID RECEPTORS IN CIRCULATIVE CANCER CELLS AND TREATMENT
US8557531B2 (en) * 2006-04-18 2013-10-15 Wellstat Biologics Corporation Detection of circulating endothelial cells

Also Published As

Publication number Publication date
CA2684265A1 (en) 2008-10-30
US20100120072A1 (en) 2010-05-13
EP2145188A4 (en) 2010-06-30
JP2010525326A (ja) 2010-07-22
EP2145188A1 (en) 2010-01-20
CN101663584A (zh) 2010-03-03
WO2008130910A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
MX2009011228A (es) Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.
HK1103439A1 (en) Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment
MX2017015260A (es) Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer.
MX2018009738A (es) Anticuerpos monoclonales de proteína ns1 anti-virus del dengue.
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
EP4306934A3 (en) Bodily emission analysis
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
MY198081A (en) Urinalysis device and dry reagent for quantitative urinalysis
EP3208617A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
BR0312534A (pt) método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura
SG10201804260QA (en) Diagnostic assays and kits for detection of folate receptor 1
NZ578283A (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
EP3907509A3 (en) Diagnosis of early stage pancreatic cancer
MX2013011431A (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
WO2015057968A3 (en) Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
WO2018064013A8 (en) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
WO2015095862A3 (en) Microrna biomarkers for ovarian cancer
MX2021014963A (es) Metodos para predecir el beneficio terapeutico de la terapia con anti-cd19 en pacientes.
WO2016198833A3 (en) Methods for analysing a urine sample
WO2015048804A3 (en) Protein biomarker and uses thereof
MX2020001958A (es) Procedimientos de diagnostico y tratamiento del cancer de pulmon.
MX2020006660A (es) Biomarcadores de tolerancia inmunitaria inducida por metotrexato.
WO2019066617A3 (ko) 항 c-met 항체 및 이의 용도

Legal Events

Date Code Title Description
FG Grant or registration